Home Stocks LinkedIn Corp (LNKD) Gets a Boost on Results, Revamped Software

LinkedIn Corp (LNKD) Gets a Boost on Results, Revamped Software

Advertisement Disclosure: When you purchase through our sponsored links, we may earn a commission from our partners. By using this website you agree to our T&Cs.

BioTelemetry, Inc. (NASDAQ:BEAT), LinkedIn Corp (NYSE:LNKD) and Spirit AeroSystems Holdings, Inc. (NYSE:SPR) are this Friday’s top gainers midday. On the losing end are Community Health Systems (NYSE:CYH), Biota Pharmaceuticals Inc (NASDAQ:BOTA) and Audience Inc (NASDAQ:ADNC).

LinkedIn Climbs on Positive Results

Wireless medical technology company BioTelemetry, Inc. (NASDAQ:BEAT) hit midday up +9.58% this Friday. The Q1 George Soros buy reported its second quarter financial results yesterday. Its price is up a slight +0.94% in the last month.

Corporate social network LinkedIn Corp (NYSE:LNKD) climbed +9.06% today, thanks to positive quarterly results and a revamped version of its Sales Navigator software. Billionaire hedge fund manager Ray Dalio upped his position in LNKD to 14,000 shares during the first quarter of the year.

Up +9.03% midday, Spirit AeroSystems Holdings, Inc. (NYSE:SPR) takes the last spot on today’s list of gainers. The Wichita-based company reported a Q2 profit this week and also lifted its full-year outlook for 2014. David Einhorn initiated a position in SPR in Q1 2013 and has likely made a gain on this one, given its price has climbed +39.82% in the past year.

Biota Pharmaceuticals Falls on Failed Drug Trial

Taking the top spot on today’s list of midday losers is Community Health Systems (NYSE:CYH), down -38.91%. It is a Q1 Farallon Capital pick.

Also having a rough Friday is Biota Pharmaceuticals Inc (NASDAQ:BOTA), its price falling -22.43% midday. The explanation: its flu treatment, one of its lead drugs, failed a mid-stage study. A new Q1 buy for George Soros, Biota has lost -42.72% year-to-date.

Audience Inc (NASDAQ:ADNC) fell -17.73% midday after Chardan Capital Markets downgraded its rating of the stock from buy to neutral, also lowering its price target to $9.00. Soros purchased 421,000 ADNC shares during the fourth quarter of 2013 and reduced his allocation slightly during the first quarter of this year. The stock is down -32.13% YTD.

Our Editorial Standards

At ValueWalk, we’re committed to providing accurate, research-backed information. Our editors go above and beyond to ensure our content is trustworthy and transparent.

Editor
Investing

Which Stocks Should You Buy, and Sell, in 2026?

Dave Kovaleski5 months

Also, the 3 sectors that Wall Street analysts are most bullish about. The usual suspects dominated in 2025 as both the Communication Services and Information Technology sectors helped boost the...